DECREASING PATTERNS OF INFLIXIMAB TROUGH LEVELS IN ASYMPTOMATIC INFLAMMATORY BOWEL DISEASE PATIENTS UNDER MAINTENANCE TREATMENT WITH INFLIXIMAB; DOES IT MATTER?

被引：0
|
作者：
Orfanoudaki, Eleni
Gazouli, Maria
Foteinogiannopoulou, Kalliopi
Theodoraki, Eirini
Legaki, Evangelia
Koutroubakis, Ioannis E.
机构：
来源：
GASTROENTEROLOGY | 2020年 / 158卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Sa1890
引用
收藏
页码：S467 / S467
页数：1
相关论文
共 50 条
  • [31] Association between faecal calprotectin values and infliximab trough levels in inflammatory bowel disease patients
    Rodriguez Alonso, L.
    Serra, K.
    Santacana, E.
    Padulles, N.
    Arajol, C.
    Gilabert, P.
    Orobitg, J.
    Rodriguez-Moranta, F.
    Colom, H.
    Padulles, A.
    Bas, J.
    Guardiola, J.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S261 - S262
  • [32] Letter: infliximab de-escalation based on trough levels in patients with inflammatory bowel disease
    Paul, S.
    Roblin, X.
    Peyrin-Biroulet, L.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2015, 42 (07) : 939 - 940
  • [33] Serum trough levels of infliximab are not associated with peripheral arthralgia activity in patients with inflammatory bowel disease
    Sekhri, Shaina
    Rao, Bharat
    Mohananey, Akanksha
    Beniwal-Patel, Poonam
    Bruss, Alexandra
    Stein, Daniel J.
    Yarur, Andres J.
    BMJ OPEN GASTROENTEROLOGY, 2021, 8 (01):
  • [34] Early Infliximab Trough Levels Are Associated with Persistent Remission in Pediatric Patients with Inflammatory Bowel Disease
    Singh, Namita
    Rosenthal, Casey J.
    Melmed, Gil Y.
    Mirocha, James
    Farrior, Sharmayne
    Callejas, Silvia
    Tripuraneni, Bhavna
    Rabizadeh, Shervin
    Dubinsky, Marla C.
    INFLAMMATORY BOWEL DISEASES, 2014, 20 (10) : 1708 - 1713
  • [35] Is there a correlation between infliximab trough levels and the development of adverse events in patients with inflammatory bowel disease?
    Theodoraki, E.
    Orfanoudaki, E.
    Foteinogiannopoulou, K.
    Legaki, E.
    Gazouli, M.
    Koutroubakis, I.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S438 - S438
  • [36] Using Infliximab Trough Levels and Fecal Calprotectin Levels Together to Guide Clinical Decisions Has the Potential to Improve Outcomes in Inflammatory Bowel Disease Patients on Maintenance Infliximab Therapy
    Amin, Aditi
    Prosser, Connie
    Kroeker, Karen
    Wang, Haili
    Shalapay, Carol
    Dhami, Neil
    Fedorak, Darryl K.
    Halloran, Brendan P.
    Dieleman, Levinus A.
    Goodman, Karen
    Fedorak, Richard N.
    Huang, Vivian
    GASTROENTEROLOGY, 2016, 150 (04) : S422 - S422
  • [37] Serum trough infliximab levels: A comparison of three different immunoassays for the monitoring of CT-P13 (infliximab) treatment in patients with inflammatory bowel disease
    Malickova, Karin
    Duricova, Dana
    Bortlik, Martin
    Hind'os, Miroslav
    Machkova, Nadezda
    Hruba, Veronika
    Lukas, Martin
    Zima, Tomas
    Lukas, Milan
    BIOLOGICALS, 2016, 44 (01) : 33 - 36
  • [38] Predictors of Immunogenicity to Infliximab among Patients with Inflammatory Bowel Disease: Does Ethnicity Matter?
    Veisman, Ido
    Yablecovitch, Doron
    Kopylov, Uri
    Eliakim, Rami
    Ben-Horin, Shomron
    Ungar, Bella
    ISRAEL MEDICAL ASSOCIATION JOURNAL, 2021, 23 (12): : 788 - 793
  • [39] The Effect of Infliximab Treatment On Angiogenic Factors Levels in Patients with Inflammatory Bowel Disease
    Algaba, Alicia
    Linares, Pablo M.
    Dominguez, Irene
    Pousa, Ines D.
    Bermejo, Fernando
    Gisbert, Javier P.
    Nos, Pilar
    Rodriguez, Jose L.
    GASTROENTEROLOGY, 2009, 136 (05) : A262 - A262
  • [40] Asymptomatic hyperCKemia During Infliximab Therapy in Patients With Inflammatory Bowel Disease
    Katsanos, Konstantinos H.
    Kyriakidi, Kallirroi
    Skamnelos, Alexandros
    Christodoulou, Dimitrios K.
    INFLAMMATORY BOWEL DISEASES, 2018, 24 (06) : 1272 - 1273
12345